Comparison · NCT00293215-sae
Cohort 1 (1.0 mg/m^2) vs Cohort 2 (2.6 mg/m^2): serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Cohort 1 (1.0 mg/m^2) vs Cohort 2 (2.6 mg/m^2): serious adverse events. Trial comparisons, record NCT00293215-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00293215-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.167 | 0.0301 | 0.564 | wilson | |
| Risk in group 2 | 0.333 | 0.0615 | 0.792 | wilson | |
| Risk difference, group 1 minus group 2 | -0.167 | -0.646 | 0.314 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.5 | 0.0453 | 5.51 | log | |
| Odds ratio, group 1 over group 2 | 0.4 | 0.016 | 10 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Cohort 1 (1.0 mg/m^2) than on Cohort 2 (2.6 mg/m^2) | 6 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Cohort 1 (1.0 mg/m^2) | Subjects received 111-In-CMD-193 (3-7 mCi) IV on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 1.0 mg/m\^2 IV on Day 1 of subsequent 21-day cycles. | 1 | 6 | EG000 |
| Group 2 | Cohort 2 (2.6 mg/m^2) | Subjects received 111-In-CMD-193 (3-7 mCi) IV on Day 1 of Cycle 1. Subjects received CMD-193 at a dose of 2.6 mg/m\^2 IV on Day 1 of subsequent 21-day cycles. | 1 | 3 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- All adverse events (AEs) occurring between the first dose of study treatment and the off-study date (i.e., up to 4 months) were documented, regardless of the causal relationship to study drug.
Source ClinicalTrials.gov
Trial
- Title
- Biodistribution Study of CMD-193 in Patients With Advanced Tumours Expressing the Lewis-Y Antigen
- NCT number
- NCT00293215
- Phases
- PHASE1
- Conditions
- Neoplasms
- Interventions
- 111-Indium-CMD-193, CMD-193
- Lead sponsor
- Ludwig Institute for Cancer Research
- Results first posted
- 2020-08-10
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00293215?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00293215-sae